Infliximab - CAS 170277-31-3
Catalog number: B0084-060788
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C6428H9912N1694O1987
Molecular Weight:
144190.3
COA:
Inquire
Description:
Infliximab is a monoclonal antibody drug that is used for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and ankylosing spondylitis. It binds to tumor necrosis factor alpha (TNF-α), which plays a role in the autoimmune reation. Infliximab may lead to fatal infections yet.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
monoclonal antibody, (TNF-α), inflammations
Purity:
95%
Synonyms:
Avakine; CT-P 13; Remicade; Unii-B72hh48flu; Immunoglobulin G, anti-(human tumor necrosis factor) (human-mouse monoclonal ca2 heavy chain), disulfide with human-mouse monoclonal ca2 light chain, dimer
MSDS:
Inquire
Application:
the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and ankylosing spondylitis
Shelf Life:
2 years
Quantity:
Data not available, please inquire.
1.Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment.
Takeuchi M1, Karasawa Y1, Harimoto K1, Tanaka A1, Shibata M1, Sato T1, Caspi RR2, Ito M3. Ocul Immunol Inflamm. 2016 Apr 12:1-10. [Epub ahead of print]
PURPOSE: To examine antigen-stimulated cytokine production by Behçet disease patients (BD) before and after infliximab infusion.
2.Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M1, Christensen LA2, Gibson PR3, Gearry RB4, Fallingborg J5, Hvas CL2, Bibby BM6, Uldbjerg N7, Connell WR8, Rosella O3, Grosen A2, Brown SJ8, Kjeldsen J9, Wildt S10, Svenningsen L11, Sparrow MP3, Walsh A12, Connor SJ13, Radford-Smith G14, Lawrance IC15, Andrews JM16, Ellard K17, Bell SJ8. Gastroenterology. 2016 Apr 7. pii: S0016-5085(16)30054-3. doi: 10.1053/j.gastro.2016.04.002. [Epub ahead of print]
BACKGROUND & AIMS: Little is known about in utero exposure to and postnatal clearance of anti- tumor necrosis factor (anti-TNF) agents in neonates. We investigated the concentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance after birth, and how these correlated with drug concentrations in mothers at birth and risk of infection during the first year of life.
3.[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
Alfageme Roldán F1, Bermejo Hernando A2, Calvo González JL3, Marqués Sánchez P4. Rev Esp Salud Publica. 2016 Apr 13;90:e1-7.
in English, SpanishOBJETIVO: Los nuevos tratamientos biológicos, si bien mejoran la calidad de vida del paciente, incrementan los costes exponencialmente en relación al resto de tratamientos. El objetivo fue calcular el tratamiento más coste efectivo de los existentes para la psoriasis.
4.Quantitative bottom up analysis of infliximab in serum using protein A purification and integrated μLC-electrospray chip IonKey MS/MS technology.
Kleinnijenhuis AJ1, Ingola M1, Toersche JH1, van Holthoon FL1, van Dongen WD1,2. Bioanalysis. 2016 Apr 12:0. [Epub ahead of print]
BACKGROUND: TNO Triskelion has applied its general workflow for the development of quantitative LC-MS methods for proteins in biological matrices to the quantification of infliximab in rat serum using bottom up μLC-MS/MS. Results/methodology: The general workflow consists of sample purification, analyte processing and LC-MS analysis. In the development of a quantitative μLC-MS/MS method for infliximab in rat serum the analyte processing part and the LC-MS part were optimized, in order to meet the different sample requirements of μLC-MS as compared with UPLC-MS. Using the optimized μLC-MS/MS method the LOQ was 75 ng/ml.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Quick Inquiry

Verification code

Featured Items